Ultragenyx Pharmaceutical has announced plans to discontinue the development of the investigational treatment UX007 for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) ...

More than 90 million Americans will experience a balance disorder in their lifetime, and balance-related falls account for more than half of all accidental deaths among older adults. Many of ...

Our one-year pediatric movement disorders fellowship is designed to prepare child neurologists to become experts in the evaluation and treatment of conditions causing unwanted involuntary movements.

Recent discoveries at The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU) in Hangzhou, China, are transforming the diagnosis and treatment of paroxysmal kinesigenic ...

Dyskinesias are rare diseases characterised by sudden, involuntary movements that can affect the whole body. Two years ago, the team of Prof. Flamand-Roze and Dr. Méneret at the Paris Brain Institute ...

Ultragenyx is abandoning its glucose transporter type-1 deficiency syndrome (Glut1 DS) program after its drug UX007 missed its endpoints in a phase 3 trial of the rare genetic disorder. This doesn’t ...